Acurx Pharmaceuticals, Inc.: 10-Q filed 2022-11-10

Name: Acurx Pharmaceuticals, Inc.: 10-Q filed 2022-11-10
Creator: Acurx Pharmaceuticals, Inc.

What Acurx Pharmaceuticals, Inc. reported in its quarterly report filed 2022-11-10 (fiscal Q3 2022): 22 published measures, 70 facts as tagged in accession 0001558370-22-017408.

This filing

Form: 10-Q (quarterly report)
Filed: 2022-11-10
Fiscal period: fiscal Q3 2022
Accession: 0001558370-22-017408 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Acurx Pharmaceuticals, Inc. filings.

Reported measures

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2022-09-30	1,182,080	USD
At 2021-12-31	843,909	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2022-09-30	9,763,068	USD
At 2022-06-30	8,785,421	USD
At 2022-03-31	10,689,272	USD
At 2021-12-31	12,410,241	USD
At 2021-09-30	14,277,191	USD
At 2021-06-30	15,521,506	USD
At 2021-03-31	2,471,159	USD
At 2020-12-31	2,701,586	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-3,541,594	USD	92
2022-01-01 to 2022-09-30	-8,832,265	USD	273
2022-04-01 to 2022-06-30	-2,620,533	USD	91
2022-01-01 to 2022-03-31	-2,670,138	USD	90
2021-07-01 to 2021-09-30	-4,642,222	USD	92
2021-01-01 to 2021-09-30	-10,120,611	USD	273
2021-04-01 to 2021-06-30	-4,004,059	USD	91
2021-01-01 to 2021-03-31	-1,474,330	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	-6,046,701	USD	273
2021-01-01 to 2021-09-30	-3,513,497	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	3,695,196	USD	273
2021-01-01 to 2021-09-30	14,797,132	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2022-09-30	-35,380,574	USD
At 2021-12-31	-26,548,309	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	11,148,402	shares	92
2022-01-01 to 2022-09-30	10,551,503	shares	273
2021-07-01 to 2021-09-30	10,116,403	shares	92
2021-01-01 to 2021-09-30	7,988,563	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	11,148,402	shares	92
2022-01-01 to 2022-09-30	10,551,503	shares	273
2021-07-01 to 2021-09-30	10,116,403	shares	92
2021-01-01 to 2021-09-30	7,988,563	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-0.32	USD/shares	92
2022-01-01 to 2022-09-30	-0.84	USD/shares	273
2021-07-01 to 2021-09-30	-0.46	USD/shares	92
2021-01-01 to 2021-09-30	-1.27	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-0.32	USD/shares	92
2022-01-01 to 2022-09-30	-0.84	USD/shares	273
2021-07-01 to 2021-09-30	-0.46	USD/shares	92
2021-01-01 to 2021-09-30	-1.27	USD/shares	273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	0	USD	273

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	2,174,716	USD	273
2021-01-01 to 2021-09-30	4,482,078	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2022-09-30	10,945,148	USD
At 2021-12-31	13,254,150	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2022-09-30	1,182,080	USD
At 2021-12-31	843,909	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	3,541,594	USD	92
2022-01-01 to 2022-09-30	8,832,265	USD	273
2021-07-01 to 2021-09-30	4,642,222	USD	92
2021-01-01 to 2021-09-30	10,187,114	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	1,591,043	USD	92
2022-01-01 to 2022-09-30	3,321,623	USD	273
2021-07-01 to 2021-09-30	1,126,972	USD	92
2021-01-01 to 2021-09-30	1,313,954	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2022-09-30	11,592,609	shares
At 2021-12-31	10,215,792	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2022-09-30	10,607,341	USD
At 2021-12-31	12,958,846	USD
At 2021-09-30	14,459,046	USD
At 2020-12-31	3,175,411	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2022-09-30	45,132,049	USD
At 2021-12-31	38,948,334	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	-8,832,265	USD	273
2021-01-01 to 2021-09-30	-10,120,611	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	1,950,551	USD	92
2022-01-01 to 2022-09-30	5,510,642	USD	273
2021-07-01 to 2021-09-30	3,515,250	USD	92
2021-01-01 to 2021-09-30	8,873,160	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	3,695,183	USD	273

Inspect the source

Entity: Acurx Pharmaceuticals, Inc. / CIK 0001736243
Captured: 2026-09-21T17:25:29.911Z
SEC response SHA-256: 3ff72a27b12e3bbf2238c568e6d540d3ffd8acf36c9060b3da0911bb5446b5e9

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001736243.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))